Patents
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
08/2006
08/17/2006WO2006084833A1 Monohydrochloride salt of 1- [3- [3- (4-chlorophenyl) propoxy] propyl] -piperidine
08/17/2006WO2006084768A1 Pharmaceutical composition for the prevention and treatment of cancer
08/17/2006WO2006084765A1 Use of sodium channel blockers and their analogues for the treatment of nicotine dependency
08/17/2006WO2006084761A1 Crystalline polymorphs of benazepril hydrochloride
08/17/2006WO2006084758A1 Human monoclonal antibody specific for lipopolysaccharides (lps) of the pseudomonas aeruginosa iats o11 serotype
08/17/2006WO2006084757A2 Combination of ca/mg salt of valsartan with an antidiabetic agent
08/17/2006WO2006084694A2 Use of the mcm8 gene for the preparation of a pharmaceutical composition
08/17/2006WO2006084688A1 HIV protease inhibitors
08/17/2006WO2006084687A1 Use of zeaxanthin for the treatment of diseases of the peripheral retina
08/17/2006WO2006084684A1 Pharmaceutical compositions comprising nebivolol and a hydrophilic polymer
08/17/2006WO2006084683A1 Methods for improving drug disposition
08/17/2006WO2006084634A1 Pyrazolo-pyrimidine derivatives as mglur2 antagonists
08/17/2006WO2006084573A1 Food products comprising hydrolysed milk solids with improved taste
08/17/2006WO2006084560A1 Composition comprising peptide
08/17/2006WO2006084547A1 Compositions containing biguanide
08/17/2006WO2006084477A1 Use of a lyophilised bacterial lysate for the prevention of tuberculosis relapse
08/17/2006WO2006084469A1 Cyclodextrin cyanohydrins
08/17/2006WO2006084412A1 Method for purifying noroxymorphone compounds
08/17/2006WO2006084410A1 New macrolides
08/17/2006WO2006084389A1 Method for purifying noroxymorphone compounds
08/17/2006WO2006084369A1 Diamine calcium channel blockers
08/17/2006WO2006084368A1 Fluorinated phno and analogs thereof
08/17/2006WO2006084353A1 Stabilized compositions for topical administration and methods of making same
08/17/2006WO2006084338A1 Novel tubulin polymerisation inhibitors
08/17/2006WO2006084322A1 Treatment method for modifying tissue passive electrical conductance
08/17/2006WO2006084312A1 Method of promoting hair growth
08/17/2006WO2006076646A3 Heteroaryl substituted quinolin-4-ylamine analogues
08/17/2006WO2006071995A9 Serine amino acid derived prodrugs of propofol, compositions, uses and crystalline forms thereof
08/17/2006WO2006071966A3 Rapamycin compounds in the treatment of neurofibromatosis type 1
08/17/2006WO2006071848A9 Glycolipids and analogues thereof as antigens for nk t cells
08/17/2006WO2006071601A3 Therapeutic compositions for intranasal administration of ketorolac
08/17/2006WO2006067311A3 Cdc25 phosphatase inhibitors
08/17/2006WO2006066950A3 Tricyclic aminoalcohols, methods for producing the same and their use as anti-inflammatory agents
08/17/2006WO2006066645A3 Use of a container made of a plastic material containing an inorganic additive
08/17/2006WO2006066260A9 Compositions of and methods for producing phosphorus-chiral monomers and oligomers
08/17/2006WO2006065780A3 Combinations of therapeutic agents for treating cancer
08/17/2006WO2006064324A3 Heterocycloalkyl-benzyl substituted hydroxyethlamines
08/17/2006WO2006063128A3 Methods, assays and compositions for treating retinol-related diseases
08/17/2006WO2006063039A3 3, 6-bicyclolides
08/17/2006WO2006062723A3 Combination of immuno gene therapy and chemotherapy for treatment of cancer and hyperproliferative diseases
08/17/2006WO2006060730A3 Potassium salt of an hiv integrase inhibitor
08/17/2006WO2006060122A9 Cardiotonic compounds with inhibitory activity against beta-adrenergic receptors and phosphodiesterase
08/17/2006WO2006060110A3 Process for preparing {3-[2(r)-[(1r)-1-[3,5-bis(trifluoromethyl)phenyl]ethoxy]-3(s)-(4-fluorophenyl)morpholin-4-yl]methyl]-5-oxo-4,5-dihydro-[1,2,4]-triazol-1-yl}phosphonic acid
08/17/2006WO2006059357A9 Use of compounds that interfere with the hedgehog signaling pathway for the manufacture of a medicament for preventing, inhibiting, and/ or reversing ocular diseases related with ocular neovascularization
08/17/2006WO2006059252A3 Methods and fluorinated compositions for treating amyloid-related diseases
08/17/2006WO2006059164A3 Pyrrolopyridine-2-carboxylic acid amides
08/17/2006WO2006057912A3 Rasagiline orally disintegrating compositions
08/17/2006WO2006056144A3 Osmotic device containing licofelone
08/17/2006WO2006055734A3 3-phenyl-pyrazole derivatives as modulators of the 5-ht2a serotonin receptor useful for the treatment of disorders related thereto
08/17/2006WO2006054921A3 Anti-inflammatory extract and agent and method for the production thereof
08/17/2006WO2006054315B1 Nonaqueous liquid parenteral aceclofenac formulation
08/17/2006WO2006054278A8 Variants of pigment epithelium derived factor and uses thereof
08/17/2006WO2006053184A3 Methods for treating or preventing a vascular disease
08/17/2006WO2006053150A3 Pharmaceutical compositions for topical application on the treatment of age-related macular degeneration and ocular hypertension
08/17/2006WO2006052976A3 Improved dosing regimen of temozolomide for treating cancer based on the patient’s mgmt level
08/17/2006WO2006052768A3 Process for preparing quinoline compounds and products obtained therefrom
08/17/2006WO2006052373A3 Method for treating hiv infection through co-administration of tipranavir and etravirine
08/17/2006WO2006047362A9 Transdermal delivery systems
08/17/2006WO2006046135A3 Pyrazolo[4,3-d] pyrimidine derivatives useful as pde-5 inhibitors
08/17/2006WO2006045578A3 Process for the preparation of ibandronate
08/17/2006WO2006044753A3 Chemical compounds
08/17/2006WO2006044509A3 Methods of treating vascular injuries
08/17/2006WO2006036872A3 Targeting opposite strand replication intermediates of single-stranded viruses by rnai
08/17/2006WO2006034325A3 Method of treatment for or protection against lymphedema
08/17/2006WO2006031782A3 Salvinorin derivatives as opioid receptor ligands
08/17/2006WO2006031357A3 Fluorescent fused-ring triazoles that inhibit cell proliferation and uses thereof
08/17/2006WO2006029182A3 Use of mdl-100,907 for treatment of allergic and eosinophil mediated diseases
08/17/2006WO2006026533A8 Methods of treatment of amyloidosis using ethanol cyclicamine derivatives aspartyl protease inhibitors
08/17/2006WO2006023158A3 Mineralocorticoid receptor modulator compounds and methods, and pharmaceutical compositions containing these compounds
08/17/2006WO2006021213A3 Vasopressin v1a antagonists
08/17/2006WO2006017594A3 Fatty-acid derivatives of glycerol for treating microbial infections
08/17/2006WO2006008636A3 Processes for the preparation of zolpidem and its hemitartrate
08/17/2006WO2006007532A3 2-substituted heteroaryl compounds
08/17/2006WO2006007384B1 Antibiotics containing borinic acid complexes and methods of use
08/17/2006WO2006007377A3 Methods of screening for bridge-1-mediated disorders, including type ii diabetes
08/17/2006WO2006002383A3 2-aminoarylcarboxamides useful as cancer chemotherapeutic agents
08/17/2006WO2006001982A3 Methods and compositions for treating neuropathies
08/17/2006WO2006000555A3 Novel unsaturated tetracyclic tetrahydrofuran derivatives
08/17/2006WO2005123068A3 Methods of dealying alzheimer’s disease progression using a beta-amyloid precursor protein inhibitor and a hmg coa reductase inhibitor
08/17/2006WO2005120520A3 Compositions and methods for diagnosis and treatment of chemotherapy-resistant neoplastic disease
08/17/2006WO2005117895A3 Compositions comprising meloxicam
08/17/2006WO2005115383A3 Substituted triazoles as modulators of ppar and methods of their preparation
08/17/2006WO2005115363A3 Method for treating skeletal disorders resulting from fgfr malfunction
08/17/2006WO2005112924A3 Methods of treating cancer by inhibiting histone gene expression
08/17/2006WO2005111224A8 Water-soluble coenzyme q10 in inclusion complex with beta-cyclodextrin, process of preparing, and use thereof
08/17/2006WO2005107762A3 Certain chemical entities, compositions, and methods
08/17/2006WO2005102389A3 Combinations comprising alpha-2-delta ligands and ep4 receptor antagonists
08/17/2006WO2005102341A3 Animal cover having a temperature altering device
08/17/2006WO2005097140A3 Selective antagonists of a2a adenosine receptors
08/17/2006WO2005097058A3 Cyclodextrin inclusions complexes of pyrimidine-2,4,6-triones
08/17/2006WO2005094448A3 Methods and compositions employing 4-aminophenylacetic acid compounds
08/17/2006WO2005094323A3 Process for preparing a dipeptidyl peptidase iv inhibitor and intermediates employed therein
08/17/2006WO2005089486A3 Methods for treating alcoholism
08/17/2006WO2005086895A3 Ion channel modulators
08/17/2006WO2005084401A3 Aryl substituted purine analogues
08/17/2006WO2005079272B1 Compositions of non-steroidal anti-inflammatory drugs and decongestants or anti-histamines
08/17/2006WO2005055953A3 Methods of preventing and treating gastrointestinal dysfunction
08/17/2006WO2005048923A3 Extended release venlafaxine formulation
08/17/2006WO2005037845A8 Benzothiazole and thiazole[5,5-b] pyridine compositions and their use as ubiquitin ligase inhibitors
08/17/2006WO2005034858A3 Compositions and methods for treatment of muscle pain and muscle wasting